Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal

NCT06962007 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Neuromuscular Blockade Reversal Agent
Perioperative Complications
Anesthesia, General
Sugammadex
Monitoring, Intraoperative
Masseter Muscle Spasm

Interventions

DRUG: Sugammadex 1 mg/kg Group
DRUG: Sugammadex 2 mg/kg Group
DRUG: Sugammadex 4 mg/kg Group
DRUG: Pyridostigmine/Glycopyrrolate Group

Sponsor

Wonkwang University Hospital